健康防护系列产品

让人人掌握健康

    Rapid diagnosis of acute coronary syndrome (ACS)
    Background information

    According to the China Cardiovascular Health and Disease Report (2020), there are 330 million patients with cardiovascular disease in China, nearly 100 million high-risk groups, and cardiovascular disease deaths account for the first cause of death in urban and rural areas. The European Society of Cardiology (ESC) issued its latest guidelines for the management of acute coronary syndrome (ACS) in August 2023, which emphasize that, in addition to bedside electrocardiographic tests, Troponin is the basis for diagnosis and classification of diseases. In addition, due to the higher sensitivity and accuracy of high-sensitivity cardiac troponin (hs-cTn) in detecting myocardial injury, the new ESC guidelines recommend the 0 h/1 h rapid diagnosis/exclusion process as the first choice, and the 0 h/2 h process as the second choice (Ⅰ, B). In order to shorten the emergency stay time and save medical expenses. China's Guidelines for Rapid Emergency Diagnosis and Treatment of Acute Coronary Syndromes (2019) require the detection of biological markers including cTn (hs-cTn) and CK-MB in patients with suspected ACS, as well as the detection of BNP or NT-proBNP and D dimer.

    Solution

    Xinlandao (Tianjin), the holding company of Hongbo Gene, independently developed and produced the automatic single-part chemiluminescence immunoanalyzer (POCT), which relies on the magnetic particle chemiluminescence technology with independent intellectual property rights to develop and produce small, single-part, automatic immunoanalyzer. The equipment is simple to operate, the reagent strip contains all consumables, can carry out hs-cTnI detection, and the results can be obtained within 20 minutes, fully meeting the requirements of the chest pain center.

    Test items include:
    • hs-cTnI
      • MYO
      • CK-MB
      • h-FABP
      • NT-proBNP